Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?
by Zacks Equity Research
Both Merck and Pfizer reported upbeat first-quarter results on May 1
Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Universal Health (UHS) posts a solid Q1 driven by higher revenues.
Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance
by Zacks Equity Research
Strong performance across segments supports Anthem's (ANTM) first-quarter results.
Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered
by Zacks Equity Research
Centene (CNC) delivers strong first-quarter results on the back of significant membership growth.
The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
by Zacks Equity Research
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.
MS, USB, ABT & TXT Leads Q1 Earnings
by Zacks Equity Research
MS, USB, ABT & TXT Leads Q1 Earnings
Q1 Earnings Keep Markets in the Green: MS, USB, ABT & TXT
by Mark Vickery
We are still in the early stages so far, but overall results have been notably better than expected.
Abbott (ABT) Beats on Earnings and Revenues in Q1
by Zacks Equity Research
Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.
5 Amazing Earnings Charts This Week
by Tracey Ryniec
It's not easy to beat the estimate nearly every quarter for years. But these 5 companies are doing it.
Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Strong revenue opportunity from various Oncology and Imaging Component products is likely to drive Varian Medical (VAR) in Q2.
Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?
by Zacks Equity Research
Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.
3 Stocks to Buy Ahead of Earnings
by Benjamin Rains
Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won't lead to a much larger conflict. The strikes also coincided with the real start of first quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently.
Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?
by Zacks Equity Research
Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.
Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) developments on the da Vinci platform are a positive, while intense competition raises concern.
Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Medical devices business in Q1.
Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to ride high on strength in EPD business in Q1.
Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.
Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.
Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device
by Zacks Equity Research
Abbott (ABT) adopts ways to strengthen Heart Failure business under the Medical Device segment.
Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire
by Urmimala Biswas
Chances of a retaliation from China leads to widespread losses in the medical device sector.
Edwards (EW) Completes Enrollment for PARTNER 3 Sub-Study
by Zacks Equity Research
Edwards' (EW) near-term product pipeline looks quite encouraging.
Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK
by Zacks Equity Research
Baxter (BAX) steadily focuses on improving its Advanced Surgery business.
Can Boston Scientific's Pain be a Boon for Edwards & Others?
by Sweta Jaiswal
Boston Scientific delaying the re-introduction of Lotus Valve devices provides an edge to its competitors in the highly lucrative TAVR market.